Dr Vityala Yethindra from Telangana, India, is the recipient of the MedEngage Award and Scholarship under the “Champion of the Champions” category – launched by Metropolis Healthcare Ltd. – awarded at MedEngage Scholarship Summit 2021.
Dr. Vityala Yethindra
Dr Yethindra received the award for his inspiring research works and academics, which have contributed markedly to the field of medical literature. He is a recent MD (General Medicine) graduate from the International University of Kyrgyzstan. Currently, he is the world’s youngest medical scientist and has achieved 12 world records to date in such categories as youngest person to write a trilingual book, most medical courses (51) related certificates received in 9 days, fastest research study accomplished in the world, and first person in the world to complete 20 medical courses at 10 universities in 9 days. He holds the Guinness World Record for the “longest title of a book.” In 2020-2021, he received Mahatma Gandhi National Award from Mahatma Gandhi Global Peace Forum, and Karmaveer Chakra Award instituted by iCONGO in partnership with United Nations (UN) for his contributions to humanity, peacebuilding, education, and medical research. He has participated in 14 international conferences, delivered presentations, and won eight awards at conferences. He is the author of two books, and of 23 research articles in reputable journals.
ADVERTISEMENT
MedEngage, a corporate social responsibility initiative by Metropolis Healthcare Ltd., aims to assist deserving medical students in India through scholarships, research grants, and certificate courses. Metropolis launched its first edition of the “MedEngage Scholarship Summit 2018” on December 9, 2018, in Mumbai. In 2021, Metropolis awarded scholarships to 70 medical students at the virtual second edition of the Summit. Out of six categories, the “Champion of the Champions” Scholarship Award is the highest category presented to a student who achieved outstanding academic performance, participated in conferences, delivered presentations, and authored research articles for publication in journals while pursuing various interests.
“I am elated and humbled to be recognized,” Dr Yethindra said. “This is a great initiative and opportunity from Metropolis for talented medical students and doctors in India.”
As a researcher, Dr Yethindra proved that fluoxetine and doxycycline inhibit SARS-CoV-2 replication in-vitro; evaluated the safety and efficacy of umifenovir, heparin, itolizumab, and rivaroxaban in patients with COVID-19; and achieved positive results. He was the first to report and publish new and rare case reports on diseases such as epilepsy, neurofibromatosis, and ischemic stroke. He assisted in the development of remdesivir, which inhibits SARS-CoV and MERS-CoV in-vitro, and developed a VYTR hypothesis for the treatment of COVID-19. Remdesivir is a life-saving drug in many countries, including India.
Yethindra says that he is delighted and excited to receive this prestigious award: “At the end of the day, we all work for solidarity to succeed, irrespective of our profession. That is what we all expect even if our dreams, inspirations, and aspirations differ; our shared target is to further develop and succeed.”
Dr Vityala Yethindra shows promise as a future superstar in medical research.
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
